Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event Averted, Raising Questions of Sustainability
Adjuvant therapies are often approved based on composite, surrogate endpoints with high costs per event averted
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD Have a Survival Advantage Over Those Who Received ABVD Regimen
Data from a median of 6 years follow-up from the ECHELON-1 study
Only a Quarter of Phase III Studies Demonstrated Improved QoL in Advanced Cancer Setting
Clinical study publications frequently frame unimproved quality of life outcomes in a positive way
EMA Recommends Extension of Therapeutic Indications for Ibrutinib
New indication concerns its use in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia
Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy in Previously Treated HER2-Low Unresectable or Metastatic Breast Cancer
Practice changing results of the DESTINY-Breast04 study
Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has a Substantial Clinical Impact for Young Patients with Solid Tumours
Findings from the GAIN/iCat2 Study in patients with extracranial solid tumours
FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
Evidence for efficacy is based on the results from the TRANSFORM and PILOT studies
Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the Outcomes of Patients with Eight Common Cancer Types on Specific Therapies
Findings from a large-scale computational analysis
EMA Recommends Granting a Marketing Authorisation for Asciminib
It is a new therapeutic option for adults with Philadelphia chromosome‑positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors
Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion of Underexposed Patients
Findings from the Dutch Pharmacology Oncology Group - Therapeutic Drug Monitoring study show that pharmacokinetically guided dose-adjustments of oral targeted therapies are feasible in clinical practice
Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control, and HRQoL
Findings from the PRO-TECT (Alliance AFT-39) cluster randomised study should be interpreted provisionally pending results of the primary outcome of overall survival
EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab
Vegzelma is highly similar to the reference product Avastin, which was authorised in the EU in January 2005